It is therefore important to identify the mechanisms responsible for NOTCH1 activation in CLL to discover new therapeutic options for patients with hyperactive NOTCH1 signaling even without NOTCH1 mutations. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.